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Abstract
Background: This study is to determine the seroprevalence of the pandemic influenza A H1N1 virus (pH1N1) in Taiwan
before and after the 2009 pandemic, and to estimate the relative severity of pH1N1 infections among different age groups.
Methodology/Principal Findings: A total of 1544 and 1558 random serum samples were collected from the general
population in Taiwan in 2007 and 2010, respectively. Seropositivity was defined by a hemagglutination inhibition titer to
pH1N1 (A/Taiwan/126/09) $1:40. The seropositivity rate of pH1N1 among the unvaccinated subjects and national
surveillance data were used to compare the proportion of infections that led to severe diseases and fatalities among
different age groups. The overall seroprevalence of pH1N1 was 0.91% (95% confidence interval [CI] 0.43–1.38) in 2007 and
significantly increased to 29.9% (95% CI 27.6–32.2) in 2010 (p,0.0001), with the peak attack rate (55.4%) in 10–17 year-old
adolescents, the lowest in elderly $65 years (14.1%). The overall attack rates were 20.6% (188/912) in unvaccinated subjects.
Among the unvaccinated but infected populations, the estimated attack rates of severe cases per 100,000 infections were
significantly higher in children aged 0–5 years (54.9 cases, odds ratio [OR] 4.23, 95% CI 3.04–5.90) and elderly $ 65years
(22.4 cases, OR 2.76, 95% CI 1.99–3.83) compared to adolescents aged 10–17 years (13.0 cases). The overall case-fatality rate
was 0.98 per 100,000 infections without a significant difference in different age groups.
Conclusions/Significance: Pre-existing immunity against pH1N1 was rarely identified in Taiwanese at any age in 2007.
Young children and elderly – the two most lower seroprotection groups showed the greatest vulnerability to clinical
severity after the pH1N1 infections. These results imply that both age groups should have higher priority for immunization
in the coming flu season.
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Introduction
The 2009 pandemic influenza A H1N1 virus (pH1N1) was
initially identified in Mexico and United States during March and
April of 2009, subsequently transmitted in communities across
North America within weeks, and identified in many areas of the
world by May 2009 [1–5]. On June 11, 2009, the World Health
Organization (WHO) declared a global pandemic [6]. Worldwide
transmission of the pH1N1 virus continued, and most countries
experienced one or two epidemic waves before the end of the
pandemic [7–10]. In Taiwan, the first laboratory confirmed case
was identified on May 20, the first severe complicated case was
reported on July 17, and the first fatal case was reported on July
31. As of August 31, 2010, a total of 983 laboratory confirmed
severe cases were reported to the Taiwan Centers for Diseases
Control (CDC) and 50 of them died. Two major waves occurred
between July and December of 2009, and only dispersed cases
appeared in 2010 (Figure 1).
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24440To better understand the population’s immunity against pH1N1
in Taiwan before and after the pandemic, we conducted a
seroepidemiology study 8 months after the last wave of the
epidemic. The epidemiological factors associated with seropositivity
were explored. Combining the seroprevalence data from the
unvaccinated subjects and the national epidemiological surveillance
data of severe and fatal cases, we estimated the extent of the pH1N1
infections in the community and compared the age-stratified
severity of pH1N1 infections. The findings from this study should
provide useful information for national public health authorities in
the preparedness of the pandemic influenza in the future.
Results
Seroprevalence of pH1N1 in 2007 and 2010
The overall seroprevalence of pH1N1 in Taiwan estimated by
hemagglutination inhibition (HI) assay was 0.91% (14 of 1544
samples) and 29.9% (466 of 1558 samples) in 2007 and 2010,
respectively. The seropositivity in baseline samples before the
global pandemic was not confined to the elder population, but it
was scattered among subjects beyond the school ages (median 51.0
years, range 14.0–89.8 years). In the post-pandemic period,
seropositivity was significantly higher among subjects ,18 years
old compared to subjects $18 years old (38.9% vs. 26.7%,
respectively, p ,0.0001). The age-specific distribution of seropos-
itivity rates disclosed an increasing trend from young children ,4
years old (23.3%) to a peak in adolescents at 10–17 years of age
(55.4%; Table 1). The seropositivity rate ranged from 29.7% to
33.0% in adults 18–44 years of age and declined to a nadir
(14.1%) in the elderly $65 years old.
The geometric mean titers (GMTs) of HI among each age
group are displayed in Table 1. In the pediatric population the
GMT was higher for subjects at the ages of ,2 years (64.56128.3)
and 10–17 years (52.1656.0) than subjects at the age of 2 to 9
years (37.6649.1) in the post-pandemic samples. The GMT of HI
among the adult populations generally followed the trend of
seropositivity and declined from 38.0 in subjects aged 18–24 years
to the lowest level (23.2613.5) in the elder population $65 years.
The microneutralization (MN) titers were measured in 336
randomly selected samples and a strong correlation was identified
between the MN and HI titers (Pearson correlation coefficient
0.85291, p,0.0001). A MN titer of $1:80 was identified in 3.1%
and 32.4% of pre-pandemic and post-pandemic samples, respec-
tively. Figure 2 displays the age-specific distribution of seroprev-
alence and GMTs of MN assay, which are very similar to the
patterns generated by HI assay. For instance, the seropositive rate
in 2010 peaked at the age of 10–17 years and was significant
higher in children ,18 years old than in adults $18 years (39.8%
vs. 25.6%, p=0.0461). The decline of seropositive rate with age in
adult population was also compatible with the results of HI assay.
Seropositivity in unvaccinated population and the age-
stratified severity of pH1N1 infections
Among the 912 subjects without immunization against pH1N1,
188 (20.6%) had an HI titer $1:40. The age-specific distribution
of seropositivity in unimmunized subjects was similar to the trend
Figure 1. National epidemic surveillance data of 2009 pandemic influenza A H1N1 in Taiwan.
doi:10.1371/journal.pone.0024440.g001
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occurring in children 6–9 and 10–17 years of age (47.8% and
47.7%, respectively) and two significant declining trends toward
the extremes of the age spectrum (p=0.0323 for subjects ,10
years old, and p,0.0001 for subjects $10 years old). Based on the
assumption that the incidences of natural infections in the
unimmunized population were proportional to the whole
population, we compared the severity of infection between each
age group and the three regions of study (Table 2). The greatest
case-serious infection rate occurred in children 0–5 years of age
(54.8–55.0 cases/100,000 infections), which was approximately
four folds (odds ratio [OR] 4.23, 95% confidence interval [CI]
3.04–5.90) higher than the rate in adolescents 10–17 years of age
(13 cases/100,000 infections). The elderly $65 years also had
nearly three folds higher case-serious infection rate compared to
adolescents (OR 2.76, 95% CI 1.99–3.83). The overall case-
fatality rate was 0.98 per 100,000 infections without significant
difference in age distributions.
Factors associated with pH1N1 seropositivity in all
participants
Seropositivity was significantly associated with age and the
residing region of the subjects, but not with the other
demographics (i.e., socioeconomic background including educa-
Figure 2. Geometric mean titers and seropositivity rates among different age groups of Taiwanese before and after 2009
pandemic, estimated by microneutralization assay.
doi:10.1371/journal.pone.0024440.g002
Table 1. Age-specific seroprevalence and geometric means of hemagglutination inhibition titer to novel influenza A (H1N1) in
Taiwan during the pre-pandemic (2007) and post-pandemic (2010) periods.
Age, yrs HI titers to 2009 pandemic influenza A (H1N1)
2007 (n=1544) 2010 (all subjects, n=1558)
2010 (unimmunized subjects,
n=912)
GMT (95% CI)
% with titer
$40 (95% CI) GMT (95% CI)
% with titer
$40 95% CI) GMT (95% CI)
% with titer
$40 (95% CI)
,2 8.8 (7.4–10.3) 0.0 (-) 64.5 (20.7–108.3) 24.2 (9.6–38.9) 77.0 (14.7–139.2) 17.4 (1.9–32.9)
2–3 7.7 (6.4–9.0) 0.0 (-) 45.7 (21.3–70.1) 22.6 (11.4–33.9) 37.6 (18.7–56.6) 23.5 (3.4–43.7)
4–5 7.4 (6.1–8.8) 0.0 (-) 35.8 (30.3–41.3) 32.1 (24.3–39.9) 36.6 (27.6–45.5) 28.4 (17.6–39.2)
6–9 8.0 (6.8–9.2) 0.0 (-) 35.0 (28.8–41.2) 42.9 (31.3–54.5) 38.3 (24.2–52.3) 47.8 (27.4–68.2)
10–17 9.8 (8.6–11.0) 1.33 (0–3.17) 52.1 (42.1–62.1) 55.4 (46.5–64.2) 52.8 (32.6–73.0) 47.7 (33.0–62.5)
18–24 7.9 (6.9–8.8) 0.63 (0–1.86) 38.0 (28.5–47.5) 29.7 (22.5–36.9) 29.2 (24.8–33.6) 22.2 (14.7–29.8)
25–34 8.9 (7.2–10.6) 1.03 (0–2.44) 32.8 (28.8–36.8) 32.9 (26.9–38.9) 26.2 (23.3–29.1) 18.9 (12.6–25.2)
35–44 8.2 (6.5–9.9) 0.51 (0–1.51) 36.7 (29.5–43.9) 33.0 (26.8–39.3) 24.5 (22.8–26.3) 20.1 (13.5–26.8)
45–54 6.4 (5.8–7.0) 0.50 (0–1.48) 33.2 (26.4–40.0) 24.9 (19.1–30.6) 26.3 (21.3–25.9) 14.6 (8.7–20.5)
55–64 7.3 (6.3–8.3) 1.90 (0–4.03) 25.9 (23.8–28.0) 20.2 (14.2–26.3) 23.8 (21.8–25.9) 15.4 (8.5–22.3)
$65 7.7 (6.8–8.5) 1.79 (0.05–3.54) 23.2 (21.0–25.4) 14.1 (8.5–19.7) 21.9 (20.5–23.4) 11.8 (5.3–18.4)
Overall 8.0 (7.6–8.4) 0.91 (0.43–1.38) 35.2 (32.8–37.6) 29.9 (27.6–32.2) 29.5 (27.1–31.8) 20.6 (18.0–23.2)
Abbreviations: GMT, geometric mean titer; CI, confidence interval.
doi:10.1371/journal.pone.0024440.t001
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size, or underlying conditions; Table S1). Subjects living in Taipei
had a lower seropositivity rate (26.1%) compared to those in
Taoyuan (31.3%, p=0.0524) or Tainan (33.3%, p=0.0106).
Compared to the general population, pregnant women appeared
to have a lower seroprotection rate (30.4% vs. 20.0%, respectively)
and GMT of HI (log titer, 1.43 vs. 1.42, respectively), but this did
not reach statistical significance. Seropositivity was significantly
higher for subjects with a history of influenza-like illness (ILI;
p=0.0308) and with vaccination against pH1N1 after June 2009
(p,0.0001). A higher rate was also evident in 52 subjects with
laboratory evidence of pH1N1 infection (Table S1), including a
positive result for the flu A rapid antigen test (p=0.0028),
hospitalization due to flu A (p=0.0150) and ever on anti-flu
medication (p=0.0002). The significant factors associated with
GMT of HI were similar to those in the seropositivity analysis
except for region of sampling, for which the GMT of HI did not
differ significantly (p=0.1449).
Multivariate logistic regression analysis identified age ,18 years
(adjusted OR [aOR] 1.455, 95% CI 1.073–1.973, p=0.0158), any
laboratoryevidenceofpH1N1infection(aOR3.804,95%CI1.719–
8.418, p=0.0010), and immunization against pH1N1 (aOR 3.151,
95% CI 2.402–4.134, p,0.0001) as independent factors association
with pH1N1 seropositivity. The geographic variables (Taoyuan vs.
Taipei, p=0.2826; Tainan vs. Taipei, p=0.2421) and ILI
(p=0.3041) were not identified as significant factors in this analysis.
Factors associated with pH1N1 seropositivity in
unvaccinated participants
The analysis of epidemiological factors associated with seropos-
itivity in unimmunized subjects is displayed in Table S2. Age and
laboratory evidence of infection were the only two factors associated
with pH1N1 seropositivity in the multivariate logistic regression
analysis. Compared to the elderly ($65 years old), children aged 6–
9 years and adolescents aged 10–17 years had a 6.2- and 6.5-fold
higher incidence of seropositivity (p=0.0083 and 0.0003), respec-
tively. With laboratory evidence suggesting pH1N1 infection was
associated with a 3.8-fold higher rate of seropositivity.
Discussion
Timely seroprevalence studies have been considered a more
precise and reliable measure for estimating the extent of influenza
infection in the community when compared to the surveillance
systems based on clinical presentations (e.g., influenza-like illness)
or laboratory confirmation, given that asymptomatic and most
mild symptomatic patients do not seek medical attention [11].
However, most of the existing seroprevalence studies of the 2009
influenza A pandemic utilized convenient samples of residual
serum from clinical laboratories or from blood donors, which
could have resulted in under or over-estimates due to the selection
bias [8,12,13,14]. The pediatric population was frequently under-
representative in these studies, which further compromised the
precise estimate for the overall population. In the current study,
the use of random samples from subjects at all ages should have
allowed more accurate estimates of overall and age-specific
seroprevalence of pH1N1 in the three studied regions of Taiwan.
These areas resided a total of 10.3 million people, accounting for
44.9% of the whole population on the island. The seroepidemi-
ology data before and after the pandemic along with the
information for factors associated with post-pandemic seropositiv-
ity should be a useful reference for the national vaccine strategy
and future public health interventions.
Table 2. Estimates of age-specific rates of serious infections and fatalities among the general population with pandemic influenza
A virus infections in Taiwan.
Character Severe complicated cases Fatal cases
No.
Case-serious infection rate
(95% CI) per 100,000
infections Odds ratio (95% CI) No.
Case-fatality rate (95% CI)
per 100,000 infections
Odds ratio
(95% CI)
Age (years)
,2 17 54.9 (28.8–81.0) 4.2 (2.5–7.2) 0 … …
2–3 23 55.0 (32.6–77.5) 3.1 (1.8–5.3) 0 … …
4–5 31 54.8 (35.5–74.0) 4.2 (2.8–6.5) 1 1.77 (0–5.23) 4.63 (0.42–
51.06)
6–9 52 24.6 (17.9–31.3) 1.9 (1.3–2.7) 0 … …
10–17 68 13.0 (9.9–16.1) Referent 2 0.38 (0–0.91) Referent
18–24 43 23.1 (16.2–30.0) 1.8 (1.2–2.6) 4 2.15 (0.04–4.25) 5.63 (0.97–
30.73)
25–34 58 16.4 (12.2–20.6) 1.3 (0.9–1.8) 2 0.56 (0–1.35) 1.48 (0.21–
10.50)
35–44 45 18.3 (13.0–23.7) 1.4 (0.97–2.1) 4 1.63 (0.03–3.23) 4.27 (0.78–
23.34)
45–54 46 17.7 (12.6–22.8) 1.4 (0.9–2.0) 3 1.15 (0–2.45) 3.02 (0.50–
18.07)
55–64 30 23.1 (14.9–31.4) 1.8 (1.2–2.7) 2 1.54 (0–3.68) 4.04 (0.57–
28.69)
$65 47 22.4 (16.0–28.8) 2.8 (2.0–3.8) 4 1.91 (0.04–3.78) 5.0 (0.92–
27.30)
Overall 460 20.4 (18.6–22.3) 22 0.98 (0.57–1.39)
doi:10.1371/journal.pone.0024440.t002
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lence of approximately 30% in the general population after the
2009 pandemic, with the peak incidence in adolescents 10–17
years old and two declining trends toward the extremes of the age
spectrum. The relatively low rate of seroprotection in young
children and the elderly required further attention since they were
the groups most vulnerable to severe influenza infections. As
shown in the current study, young children 0–5 years of age with
pH1N1 infections had greater than four–fold higher chance of
developing severe diseases compared to adolescents 10–17 years of
age. Greater disease severity was also identified in the elderly
population. The finding was in contrast to the observation that
young adults accounted for a majority of severely infected cases in
the case-series studies [15,16]. However, the observation of the
case-series studies involving only severely infected cases should be
interpreted cautiously. The greater number of serious infections
occurring in young adults can be due to a higher pH1N1 attack
rate in this population. In agreement with our analysis, a
population-based study in Hong Kong clearly showed that,
compared to children 5–14 years, elderly had 9.5 and 66 times
higher risks of ICU admission and death, respectively, if infected
with pH1N1. The severity of pH1N1 in young children (,6 years
old) were less commonly reported in population-based study. Our
data showed that young children had even greater morbidity once
infected. A strategy to improve the uptake rate of the seasonal flu
vaccines after pandemic would be needed in these two
populations.
The finding that adolescents had the highest incidence of
seropositivity could be the combined consequence of a high
vaccine coverage rate and natural infection rate in this age group.
According to the data from the Taiwan CDC, the age-specific
vaccine uptake rate in the three regions of study was 29.2% (0–3
years), 19.7% (4–6 years), 62.0% (7–9 years), 71.4% (10–12 years),
74.7% (13–15 years), 63.1% (13–18 years), 3.1% (19–24 years),
and 10.8% (.24 years) during the mass immunization campaign
against pH1N1. The highest incidence of natural infections in
schoolchildren and adolescents was also demonstrated by the
distribution of seropositivity in the unimmunized population
(Table 1) and further supported by a nation-wide virus surveillance
network that disclosed a majority (55.9%) of pH1N1 isolates from
adolescents and schoolchildren aged 6 to 15 years in 2009
epidemic (Taiwan CDC, unpublished data).
The extremely low incidence (0.91%) of subjects with pre-
existing immunity against pH1N1 in Taiwan was unexpected. The
data suggested very few Taiwanese had previous exposure to
influenza A virus with antigenic similarity to pH1N1. The finding
was in contrast to another small-scale study conducted in February
and March of 2009 by our group, which indicated a seropositivity
rate of 36.7% among 79 individuals aged $60 years [17]. The
discrepancy may be due to the selection bias of the small-scale
study, in which all of the study subjects were residents in a long-
term care facility. The low overall seroprevalence of pH1N1 in the
pre-pandemic period was also observed in selected populations in
several Asian countries, including community-dwelling adults in
Singapore (2.6%), farmers in rural southern China (1.7%), and
children in a vaccine cohort study and adult blood donors in
Hong-Kong (3.3%) [7,18,19]. In a Japanese study enrolling the
workers, residents, and patients in health care facilities, seropos-
itivity was rarely identified in subjects born after 1920 [20]. In
contrast to Asian countries, the incidences of seropositivity were
generally higher in western countries including Germany (13.1%),
the United Kingdom (14.5–17.6%), the United States (6.0%), and
New Zealand (11.9%) [11,21–23]. A substantial proportion of
individuals with pre-existing antibodies was commonly observed in
the elderly (.60 years old) in these countries. The difference in
seropositivity relative to geographic and age distribution is of great
importance for the decision-making related to public health policy.
For instance, the elderly was not among the priority groups in the
mass immunization programs in most western countries [24],
which may not be adequate in Asian countries considering the low
incidence of pre-existing immunity and the greater disease severity
of pandemic flu in this elderly population.
Except for natural infections and/or immunization, 6–17 years
of age was the only epidemiological factor independently associ-
ated with increased incidence of seropositivity in unimmunized
subjects. This data was in agreement with the finding in another
seroprevalence study in New Zealand, which indicated children
aged 5–19 years had the highest seropositivity rate and age was the
most significant risk factor [23]. This observation suggested that
children were at the greatest risk of infection during the global
pandemic of the novel H1N1 influenza, which supported the idea
that schoolchildren might be the main population accounting for
pH1N1 transmission in the community and should be listed as the
first priority for vaccination during the pandemic.
Due to the interference from the immunization program, it was
difficult to precisely estimate the infection attack rate of pH1N1 in
the general population based on serosurvey. In the current study,
the estimate of severity was preceded using the data from
unimmunized subjects based on the assumption that the
seropositivity rate in the unimmunized population was propor-
tional to whole population before immunization. Although
convincing evidence supporting this assumption was lacking and
the estimates of true infection numbers may be biased, we believed
the relative severity of infection between each age group should be
valid given that the sample subjects were randomly selected. The
distribution of seropositivity among unimmunized subjects dis-
closed a relatively low seroprotection rate in young children and
the elderly, suggesting a lower incidence of infections in these
groups compared to others. This finding was in agreement with
the seroepidemiology data before the implementation of the
immunization program in several countries and areas
[7,8,11,19,23]. With this estimate, we further observed a greater
severity of pH1N1 infection in young children and the elderly than
in adolescents and young adults, which was also consistent with the
data from Hong Kong where the highest case-hospitalization rate
occurred at the age of 5–14 years and 50–59 years (two most
extreme age groups among the study subjects) [7]. The greater
severity in young children and the elderly was also supported by a
study estimating the case-fatality rate of pH1N1 infections in
England [25].
There were several limitations in this seroprevalence study.
First, the study was conducted 8 months after the second wave of
the epidemic in Taiwan. Antibody decay to a level lower than the
defined threshold may have occurred in some subjects. Recent
studies further suggest that not all subjects developed seroprotec-
tion after pH1N1 infection and that the antibody level appears to
be associated with the disease severity at presentation [26,27]. We
also observed that among subjects with laboratory evidence of
pH1N1 infection, an HI titer greater than or equal to 1:40 was
identified in only 27 (51.9%) of 52 cases and in 6 (66.7%) of 9
hospitalized cases (Table 3). This observation suggested an
underestimate of the true number of cases with natural infections,
which inevitably led to the overestimation of the severity of
infection. Second, some epidemiological factors influencing
seropositivity may not have been collected. For instance, we have
not collected the records of seasonal influenza vaccination, which
was recently reported to have influence on the immunogenicity of
pH1N1 infection or immunization [28,29,30]. Third, the study
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data may not be generalized to the entire population of Taiwan.
We noted that the seropositivity rate varied significantly from
region to region. However, the impact of these geographic
differences was controlled in the multivariate analysis of
epidemiological risks. The significance of the identified factors
associated with seropositivity should be valid in and applicable to
the general population in Taiwan.
In summary, we observed an extremely low incidence (,1%) of
pre-existing antibodies against pH1N1 in Taiwanese before the
2009 pandemic. The overall seroprotection rate increased to
approximately 30% in the whole population and 20% in the
unimmunized population after the pandemic, with significant
variations among the different age groups. Adolescents had the
highest incidence of seropositivity owing to the high rates of vaccine
uptake and natural infections. Young children aged 0–5 years and
elderly people aged $65 years were less likely to get infections
during the 2009 pandemic; however, once infected, these
individuals had up to 4.2 times higher risk of developing a serious
complicated disease compared to adolescents at the age of 10–17
years. The finding of this seroepidemiology study enhanced our
understanding of the influenza pandemic and could help shape the
strategy of mass immunization for the future preparedness against
pandemic flu. The data is also a useful reference for the public
health authority in the coming flu season. For instance, boosting the
immunity against pH1N1 in young children and the elderly via
vaccination will be a priority in the winter of 2010 in Taiwan.
Materials and Methods
Ethics statement
A subset of serum samples collected in 2007 for other purpose
(discussed in the next section) was used to estimate the
seroprevalence of pH1N1 before the 2009 pandemic. The written
informed consent to store and use the residual plasma was
obtained from participants at the time of sample collection in
2007. The pre-pandemic serosurvey using residual serum samples
was specifically reviewed and approved by the ethical committee
in Chang Gung Memorial Hospital in July 2010. For the post-
pandemic serosurvey, informed consent was obtained from all
participants in 2010 and parental consent was further obtained for
children younger than 18 years old. All informed consents were in
written form. The post-pandemic serosurvey study was further
reviewed and approved by the ethical committee in the Chang
Gung Memorial Hospital in 2010.
Study subjects
In 2007, a Taiwan CDC-funded survey was conducted to
investigate the seroprevalence of several vaccine preventable
diseases on the main island of Taiwan. A total of 3554 plasma
samples were collected from the general population at all ages in
four regions of Taiwan during August and October of 2007. The
survey used a multi-stratified design to sample the civilians. In
each region, age- and gender-stratified sampling was conducted
using household registration records. A questionnaire-based
interview was used to collect demographic data at the time of
blood sampling. The plasma samples were frozen at 280uC
following the seroprevalence survey of vaccine preventable
diseases. In the current study, 1544 samples from subjects residing
in three of the four regions (Taipei, Taoyuan, and Tainan) were
selected for determination of antibody levels to the pH1N1. The
sample set was used to estimate the seroprevalence of pH1N1
before the 2009 global pandemic in Taiwan.
To determine the post-pandemic seroprevalence of pH1N1,
another 1558 serum samples from civilians residing in the same
regions were obtained in September to October of 2010 using the
same sampling strategy. The demographics including age, gender,
residing region, occupation, education, and socioeconomics and
information regarding underlying conditions (pregnancy, past
history of influenza-like illness, influenza rapid test, flu medication,
hospitalization due to pH1N1 in the past year, and vaccination
against pH1N1) were obtained using a questionnaire-based
interview. The laboratory evidences suggesting pH1N1 infection
during pandemic included positive influenza rapid test, hospital-
ization due to flu A or use of anti-flu medication. The use of anti-
flu medication was considered laboratory evidence of infection
because of an official announcement in Taiwan asking for
laboratory confirmation before prescribing anti-flu medication
during the 2009 pandemic. The detailed age, region, and gender
distributions of subjects in the 2007 and 2010 surveys are displayed
in Table 3.
Hemagglutination inhibition (HI) assay and
microneutralization (MN) assay
Antibody responses to the 2009 pH1N1 (A/Taiwan/126/09)
virus were detected by HI assay according to standard methods
[31]. Each serum sample was treated with a receptor-destroying
enzyme (RDE; Sigma-Aldrich, St. Louis, MO, USA) to inactivate
nonspecific inhibitors. All samples were tested in duplicate at an
initial dilution of 1:10 and a final dilution of 1:640. Positive control
serum was obtained from a patient in Chang Gung Memorial
Hospital with a laboratory-confirmed pH1N1 infection (RT-PCR
positive) at the convalescent stage. Seropositivity and seroprotec-
tion were both designated as a HI titer $1:40 to pH1N1.
Geometric mean titer (GMT) was calculated for each age group,
with a titer less than 1:10 assigned a value of 5.
Table 3. Demographics of subjects with a determined
antibody titer to novel influenza H1N1 in the pre-pandemic
(2007) and post-pandemic (2010) periods.
Character No. (%)
2007
(n=1544)
2010
(n=1558)
Age (years)
,2 60 (3.9) 33 (2.1)
2–3 64 (4.2) 53 (3.4
4–5 56 (3.6) 137 (8.8)
6–9 84 (5.4) 70 (4.5)
10–17 150 (9.7) 121 (7.8)
18–24 159 (10.3) 155 (10.0)
25–34 195 (12.6) 237 (15.2)
35–44 196 (12.7) 218 (14.0)
45–54 199 (12.9) 217 (13.9)
55–64 158 (10.2) 168 (10.8)
$65 223 (14.4) 149 (9.6)
Region
Taipei (northern Taiwan) 586 (38.0) 591 (37.9)
Taoyuan (northern Taiwan) 489 (31.7) 517 (33.2)
Tainan (southern Taiwan) 469 (30.4) 450 (28.9)
Female gender 971 (62.9) 954 (61.5)
doi:10.1371/journal.pone.0024440.t003
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randomly selected samples using an age-stratified sampling
strategy and a web-based randomization service (http://www.
random.org/lists/). The assay was done according to the protocol
provided in World Health Organization Manual on Animal
Influenza Diagnosis and Surveillance with minor modifications
[32]. Each sample was tested in four repeats at an initial dilution of
1:10 and a final dilution of 1:1280. At the final step, the MDCK
cells in wells were fixed with formalin and stained with crystal
violet. The absorbance of the cells at 570 nm wavelength was
measured spectophotometrically. A MN titer $1:80 to pH1N1
was considered seropositive.
Estimates of age-specific attack rates and severity of
pH1N1
Mass vaccination campaign against pH1N1 in Taiwan was
launched on 1 November, 2009. The populations among the
priority groups of vaccination included health-care personnel,
refugees of a strong summer storm in August 2009, pregnant
women, children aged 6 months to 6 years and persons with
catastrophic illness certificate issued by Bureau of National Health
Insurance (http://nhi-test.pstcom.com.tw/english/webdata.asp?
menu=11&menu_id=596&webdata_id=3180). Another nation-
wide in-school influenza vaccination programme targeting school-
aged children (first to 12
th grade) was launched on 16 November,
2009 [33]. The remaining populations were encouraged to receive
immunization since early December 2009. Until the end of
January 2010, approximately 5,440,000 dosages of vaccine were
administered and the uptake rate was estimated to be 23% in
whole population.
The study subjects were first divided into two groups, either
with or without vaccination against pH1N1. The occurrences of
natural infection in vaccinees before immunization were unable to
be estimated by the serosurvey. The seropositivity rate in
unvaccinated subjects was therefore used as a proxy measure to
estimate the infection attack rate in the general population. The
rationale for this estimate was that the majority of the general
population did not receive immunization during the major waves
of the pH1N1 pandemic (Figure 1). Further, the study subjects
were from random samples, and the probability of pH1N1
infection should have been similar among subjects with or without
immunization before the mass vaccination program.
The age-stratified data for severe complicated infections and
deaths associated with pH1N1 from July 2009 (the first severe case
of pH1N1 infection in Taiwan) to Aug 2010 (before the
serosurvey) were provided by the Taiwan CDC. The definition
of severe complicated influenza included laboratory confirmation
of pH1N1 by virus culture, RT-PCR, or seroconversion and at
least one of the following clinical criteria: pulmonary complication
requiring hospitalization, neurological complications, myocarditits
or pericarditis, invasive bacterial infections, or other conditions
requiring intensive care. The population statistics in the three
sampling regions in 2009 were retrieved from the official website
of the Department of Household Registration, Ministry of the
Interior, Taiwan (http://www.ris.gov.tw/ch4/static/y0s109800.
xls).
Statistics
The comparison of categorical variables between subjects was
performed with chi-square test or Fisher’s exact test where
appropriate. The difference between subjects on the numerical
variables was tested using a two-sample t-test. The case-serious
infection rates and case-fatality rates among different age groups
was compared using Mantel-Haenszel method. Multiple logistic
regression analysis was applied to explore factors associated with
seropositivity. Statistical significance was defined as p,0.05. The
data was analyzed with SAS software, version 9.1 (SAS Institute,
Cary, NC, USA).
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